Profile data is unavailable for this security.
About the company
Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
- Revenue in ILS (TTM)0.00
- Net income in ILS-9.68m
- Incorporated2008
- Employees32.00
- LocationKadimastem Ltd.Pinchas Sapir 7, Weizmann Science ParkNESS-ZIONA 74140IsraelISR
- Phone+972 89100695
- Fax+972 89100698
- Websitehttps://www.kadimastem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merchavia Holdings and Investments Ltd | 1.90m | -9.48m | 11.22m | 1.23k | -- | 1.72 | -- | 5.92 | -3.51 | -3.51 | 0.175 | 0.3884 | 0.0497 | -- | 14.75 | 1,543.16 | -24.85 | -3.37 | -25.66 | -3.46 | -- | -- | -500.16 | -185.15 | -- | -0.1024 | 0.00 | -- | 90.08 | -10.25 | -349.99 | -- | 37.97 | -- |
| Purple Biotech Ltd | 0.00 | -42.42m | 16.61m | 20.00 | -- | 0.1484 | -- | -- | -0.1381 | -0.1381 | 0.00 | 0.2915 | 0.00 | -- | -- | 0.00 | -29.17 | -37.24 | -34.22 | -41.28 | -- | -- | -- | -9,415.70 | -- | -- | 0.0075 | -- | -- | -- | 8.25 | -- | -28.45 | -- |
| Nextage Therapeutics Ltd | 1.02m | -3.36m | 27.97m | -- | -- | -- | -- | 27.37 | -0.1057 | -0.1057 | 0.032 | -0.1293 | 1.58 | -- | 10.32 | -- | -553.86 | -188.94 | -- | -423.76 | 22.60 | 33.33 | -351.17 | -2,486.19 | -- | -65.46 | -- | -- | -- | 17.99 | 30.57 | -- | -- | -- |
| Kadimastem Ltd | 0.00 | -9.68m | 51.50m | 32.00 | -- | -- | -- | -- | -2.12 | -2.12 | 0.00 | -1.94 | 0.00 | -- | -- | -- | -129.59 | -155.33 | -- | -1,831.12 | -- | -- | -- | -- | -- | -3.11 | 3.31 | -- | -- | -- | 47.14 | -- | -50.73 | -- |
| Matricelf Ltd | 0.00 | -13.66m | 63.81m | -- | -- | 2.90 | -- | -- | -0.8738 | -0.8738 | 0.00 | 1.34 | 0.00 | -- | -- | -- | -47.15 | -- | -50.89 | -- | -- | -- | -- | -- | -- | -- | 0.057 | -- | -- | -- | -10.77 | -- | -- | -- |
| X T L Biopharmaceuticals Ltd | 1.65m | -81.84m | 83.86m | 33.00 | -- | 0.4257 | -- | 50.76 | -0.3716 | -0.3716 | 0.0075 | 0.1501 | 0.0192 | -- | 0.7012 | 50,061.07 | -94.96 | -53.17 | -111.98 | -59.10 | -- | -2.33 | -4,953.75 | -1,084.42 | -- | -- | 0.00 | -- | -85.80 | -- | -7.97 | -- | -53.12 | -- |
| BioLine RX Ltd | 42.41m | -178.84m | 102.63m | 79.00 | -- | 1.69 | -- | 2.42 | -0.185 | -0.185 | 0.0422 | 0.0437 | 0.1939 | -- | 6.40 | 536,838.10 | -81.75 | -52.74 | -127.94 | -65.43 | 55.84 | -- | -421.69 | -3,501.79 | 1.05 | -519.43 | 0.4642 | -- | -- | -- | -142.93 | -- | -50.72 | -- |
| DNA Group TR Ltd | 306.00k | 15.05m | 109.25m | 14.00 | 7.08 | 1.08 | -- | 357.01 | 0.1222 | 0.1222 | 0.0025 | 0.7981 | 0.0033 | -- | 1.44 | 21,857.14 | 16.35 | -23.54 | 16.48 | -26.27 | -- | -- | 4,918.63 | -7,406.24 | -- | -- | 0.00 | -- | -45.36 | -- | 95.00 | -- | -- | -- |
| Bonus Biogroup Ltd | 0.00 | -29.19m | 130.81m | 58.00 | -- | 8.27 | -- | -- | -0.0718 | -0.0718 | 0.00 | 0.0132 | 0.00 | -- | -- | 0.00 | -64.14 | -76.10 | -74.97 | -97.19 | -- | -- | -- | -- | -- | -- | 0.4106 | -- | -- | -- | 26.29 | -- | 19.30 | -- |
Data as of Nov 25 2024. Currency figures normalised to Kadimastem Ltd.'s reporting currency: Israeli Shekel ILS
0.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Altshuler Shaham Mutual Funds Management Ltd.as of 31 Jul 2024 | 4.71k | 0.11% |
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
